The return of thalidomide. Can birth defects be prevented?

Drug Safety

Volumn 21, Issue 3, 1999, Pages 161-169

  Lary, Joseph M ^a,b   Daniel, Katherine Lyon ^a   Erickson, J David ^a   Roberts, Helen E ^a   Moore, Cynthia A ^a  

^a NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; ETRETINATE; ISOTRETINOIN; LITHIUM; METHOTREXATE; PENICILLAMINE; PHENYTOIN; TERATOGENIC AGENT; THALIDOMIDE; TRIMETHADIONE; VALPROIC ACID;

ACNE; BIRTH DEFECT; CONTRACEPTION; DRUG LEGISLATION; ERYTHEMA NODOSUM LEPROSUM; FOOD AND DRUG ADMINISTRATION; HUMAN; LEPROSY; PATIENT COUNSELING; PREGNANCY TEST; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED STATES;

ABNORMALITIES; ADULT; ANIMALS; FEMALE; HUMANS; LEPROSTATIC AGENTS; MALE; PREGNANCY; TERATOGENS; THALIDOMIDE;

EID: 0032885912     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921030-00002     Document Type: Review

References (24)

1. Wiedemann HR. Hinweis auf eine derzeitige Häufung hypo- und aplastischer Fehlbildungen der Gliedermassen. Med Welt 1961 Sep 16; 37: 1863-6
2. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961 Dec 16; II: 1358
3. Smithells RW. Thalidomide and malformations in Liverpool. Lancet 1962 Jun 16; I: 1270-3
4. Lenz W. Fragen aus der praxis: Kindliche Missbildungen nach Medikament Einnahme während der Gravidität? Dtsch Med Wochenschr 1961; 86: 2555-6
5. Burley D. Is thalidomide to blame? BMJ 1961; I: 130
6. Fullerton PM, Kremer M. Neuropathy after intake of thalidomide (Distaval). BMJ 1961; 2: 855-8
7. Lenz W. A short history of thalidomide embryopathy. Teratology 1988 Sep: 38 (3): 203-15
8. D'Arcy PF, Griffin JP. Thalidomide revisited. Adverse Drug React Toxicol Rev 1994; 13 (2): 65-76
9. Kelsey FO. Thalidomide update: regulatory aspects. Teratology 1988 Sep; 38 (3): 221-6
10. Shepard TH. Catalog of teratogenic agents. 8th ed. Baltimore (MD): Johns Hopkins University Press, 1995
11. Smithells RW, Newman CGH. Recognition of thalidomide defects. J Med Genet 1992 Oct; 29 (10): 716-23
12. Jakeman P, Smith WCS. Thalidomide in leprosy reaction. Lancet 1994 Feb 19; 343 (8895): 432-3
13. Günzler V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Saf 1992 Mar-Apr: 7 (2): 116-34
14. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994 Apr 26; 91 (9): 4082-5
15. Friedman JM, Polifka JE. Teratogenic Effects of drugs: a resource for clinicians (TERIS). Baltimore (MD): Johns Hopkins University Press, 1994
16. Dermatologic Drugs Advisory Committee. Open public hearing on NDA 18-662 Accutane (isotretinoin capsules) [transcript]. Rockville (MD): FDA Center for Drug Evaluation and Research, 1988
17. Stern RS. When a uniquely effective drug is teratogenic: the case of isotretinoin. N Engl J Med 1989 Apr 13; 320 (15): 1007-9
18. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995 Jul 13; 333 (2): 101-6
19. Holmes SC, Bankowska U, Mackie RM. The prescription of isotretinoin to women: is every precaution taken? Br J Dermatol 1998 Mar; 138 (3): 450-5
20. Chan A, Keane RJ, Hanna M, et al. Terminations of pregnancy for exposure to oral retinoids in South Australia, 1985-1993. Aust NZ J Obstet Gynaecol 1995; 35 (4): 422-6
21. Pastuzak A, Koren G, Rieder MJ. Use of the retinoid pregnancy prevention program in Canada: patterns of contraception use in women treated with isotretinoin and etretinate. Reprod Toxicol 1994 Jan-Feb; 8 (1): 63-8
22. System for Thalidomide Education and Prescribing Safety (STEPS) [prescriber folder]. Warren (NJ): Celgene Corp., 1998
23. Castilla EE, Ashton-Prolla P, Barreda-Mejia F, et al. Thalidomide, a current teratogen in South America. Teratology 1996 Dec; 54 (6): 273-7
24. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997 May 22; 336 (21): 1487-93